BERLIN (Reuters) – German biotechnology company Keur Fak said on Tuesday that the Qatar Investment Authority had bought an undisclosed stake in the company as part of raising $ 126 million in financing before a possible listing on the market.
The announcement, issued on Tuesday, is the fourth financing injection in two months, and comes a day after British drug company GSK bought a 10 percent stake for an investment of $ 171 million.
The German government also invested $ 343 million in June, against a 23 percent stake in the company, total investment during the private round of financing for about 640 million, according to Keur Fak.
The company, backed by billionaire Bill Gates, also secured a 75 million euro ($ 85.79 million) loan from the European Investment Bank earlier this month.
The company provides that it collected $ 126 million from the Qatar Investment Authority and a group of new and existing investors. A spokesman declined to disclose the size of the Qatar Investment Authority, or details of the size of the stake.
Qatar Investment Authority declined to comment.
CureFac is a pioneer in the trend to apply ribosomal DNA to develop vaccines and monoclonal antibodies for infectious diseases.
This trend, used in experimental vaccines for Covid-19 by Piontech and its partner Pfizer and Moderna, was not approved in any treatment.
Informed sources provide to Reuters that Cure Fak plans to list its shares on the stock exchange in September or October.